Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administration AACR 2026 presentations reinforce the breadth and strength of company's RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibition Strengthened financial position with financings totaling $2.2 billion in gross proceeds Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.